ClinicalTrials.gov
A service of the U.S. National Institutes of Health

Trial record **1 of 1** for: CRAD001A2310

Previous Study | Return to List | Next Study

Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection

This study has been completed.

Sponsor:
Novartis Pharmaceuticals

Information provided by (Responsible Party):
Novartis (Novartis Pharmaceuticals)

ClinicalTrials.gov Identifier:
NCT00300274

First received: March 6, 2006
Last updated: July 10, 2012
Last verified: July 2012
History of Changes

Full Text View | Tabular View | Study Results | Disclaimer | How to Read a Study Record

Results First Received: July 6, 2012

Study Type:	Interventional
Study Design:	Allocation: Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Parallel Assignment; Masking: Open Label; Primary Purpose: Treatment
Condition:	Graft Rejection
Interventions:	Drug: everolimus Drug: mycophenolate mofetil Drug: cyclosporine Drug: corticosteroids

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12

	hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Participant Flow: Overall Study

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
STARTED	282	168	271
Completed 12 Month	250	149	248
COMPLETED	236	141	226
NOT COMPLETED	46	27	45
Withdrawal by Subject	12	3	14
Lost to Follow-up	3	4	5
Death	31	20	25
Re-transplant	0	0	1

Baseline Characteristics

Hide Baseline Characteristics

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.
Total	Total of all reporting groups

Baseline Measures

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil	Total
Number of Participants [units: participants]	282	168	271	721
Age [units: years] Mean (Standard Deviation)	51.1 (10.99)	48.9 (12.06)	50.2 (11.88)	50.3 (11.6)
Gender [units: participants]				
Female	57	39	51	147
Male	225	129	220	574

Outcome Measures

Hide All Outcome Measures

1. Primary: Percentage of Participants With Composite Efficacy Failure at 12 Months [Time Frame: 12 Months]

Measure Type	Primary
Measure Title	Percentage of Participants With Composite Efficacy Failure at 12 Months
Measure Description	Composite efficacy failure was defined as Biopsy Proven Acute Rejection(BPAR) of International Society for Heart and Lung Transplantation(ISHLT) grade ≥3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up. Identification of acute rejection was based on the local pathologist's evaluation of endomyocardial biopsy slides. Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤30% or 25% lower than Baseline or Fractional shortening ≤20% or 25% lower than Baseline and/or use of inotropic treatment.
Time Frame	12 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat population included all randomized participants.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	**Everolimus 3.0 mg**	**Mycophenolate Mofetil**
Number of Participants Analyzed [units: participants]	**282**	**168**	**271**
Percentage of Participants With Composite Efficacy Failure at 12 Months [units: Percentage of participants]	**35.1**	**35.1**	**33.6**

No statistical analysis provided for Percentage of Participants With Composite Efficacy Failure at 12 Months

2. Secondary: Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months [Time Frame: 12 Months]

Measure Type	Secondary
Measure Title	Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months
Measure Description	Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or

	death and whose last day of contact was prior to Day 316 (start day of the Month 12 visit window).
Time Frame	12 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat population included all randomized participants.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	**Everolimus 3.0 mg**	**Mycophenolate Mofetil**
Number of Participants Analyzed [units: participants]	**282**	**168**	**271**
Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months [units: Percentage of participants]	**11.7**	**11.9**	**8.9**

No statistical analysis provided for Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 12 Months

3. Secondary: Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months [Time Frame: 12 Months]

Measure Type	Secondary
Measure Title	Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months
Measure Description	GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula: GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R where C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1
Time Frame	12 Months
Safety Issue	Yes

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants from the intent-to-treat population (all randomized participants) with data available for analysis.

Reporting Groups

	Description

Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	**Everolimus 3.0 mg**	**Mycophenolate Mofetil**
Number of Participants Analyzed [units: participants]	**241**	**141**	**238**
Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months [units: mL/min/1.73^2] Mean (Standard Deviation)	**59.21 (23.113)**	**59.78 (23.141)**	**64.37 (28.365)**

No statistical analysis provided for Renal Function Measured by Glomerular Filtration Rate (GFR) at 12 Months

4. Secondary: Change From Baseline in the Average Maximum Intimal Thickness at Month 12 [Time Frame: Baseline, Month 12]

Measure Type	Secondary
Measure Title	Change From Baseline in the Average Maximum Intimal Thickness at Month 12
Measure Description	Maximum intimal thickness was assessed using Intravascular Ultrasound (IVUS). IVUS is a technique for taking ultrasound pictures of the wall of an artery from inside the artery itself. It shows the thickness of the artery wall and any narrowing of the artery.
Time Frame	Baseline, Month 12
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
IVUS population consisted of randomized patients who had a minimum of 11 matched slices between IVUS images from Baseline and from Month 12 (IVUS Centers).

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Number of Participants Analyzed [units: participants]	**88**	**37**	**101**
Change From Baseline in the Average Maximum Intimal Thickness at Month 12 [units: mm] Mean (Standard Deviation)	**0.03 (0.052)**	**0.04 (0.06)**	**0.07 (0.110)**

No statistical analysis provided for Change From Baseline in the Average Maximum Intimal Thickness at Month 12

5. Secondary: Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12 [Time Frame: 12 Months]

Measure Type	Secondary
Measure Title	Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12
Measure Description	Cardiac allograft vasculopathy is defined as a 0.5 mm increase in maximum intimal thickness as measured by Intravascular Ultrasound (IVUS) in at least one matched slice between baseline and Month 12.
Time Frame	12 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
IVUS population consisted of randomized patients who had a minimum of 11 matched slices between IVUS images from Baseline and from Month 12 (IVUS centers).

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Number of Participants Analyzed [units: participants]	**88**	**37**	**101**
Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12 [units: Percentage of participants]	**12.5**	**21.6**	**26.7**

No statistical analysis provided for Percentage of Participants With Cardiac Allograft Vasculopathy (CAV) at Month 12

6. Secondary: Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With

Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12 [Time Frame: 12 Months]

Measure Type	Secondary
Measure Title	Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12
Measure Description	Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides. Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/or use of inotropic treatment.
Time Frame	12 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat population includes all randomized participants.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	**Everolimus 3.0 mg**	**Mycophenolate Mofetil**
Number of Participants Analyzed [units: participants]	**282**	**168**	**271**
Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12 [units: Percentage of participants]			
AR associated with HDC	**3.9**	**3.0**	**2.6**
BPAR of ISHLT ≥ 3A	**22.3**	**25.6**	**24.7**
Death	**7.8**	**10.1**	**4.8**
Graft loss/re-transplant	**1.4**	**3.0**	**1.8**

No statistical analysis provided for Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 12

7. Secondary: Percentage of Participants With Composite Efficacy Failure at 24 Months [Time Frame: 24 Months]

Measure Type	Secondary

Measure Title	Percentage of Participants With Composite Efficacy Failure at 24 Months
Measure Description	Composite efficacy failure was defined as Biopsy Proven Acute Rejection (BPAR) of International Society for Heart and Lung Transplantation grade ≥ 3A, Acute Rejection associated with Hemodynamic Compromise, Graft loss/Retransplant, Death or Loss to follow-up. Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides. Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline and/or use of inotropic treatment.
Time Frame	24 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat population included all randomized participants.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	**Everolimus 3.0 mg**	**Mycophenolate Mofetil**
Number of Participants Analyzed [units: participants]	**282**	**168**	**271**
Percentage of Participants With Composite Efficacy Failure at 24 Months [units: Percentage of participants]	**39.4**	**41.1**	**41.3**

No statistical analysis provided for Percentage of Participants With Composite Efficacy Failure at 24 Months

8. Secondary: Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months [Time Frame: 24 Months]

Measure Type	Secondary
Measure Title	Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months
Measure Description	Loss to follow-up for this composite endpoint included participants who did not experience graft loss/re-transplant or death and whose last day of contact was prior to Day 631 (start day of 24 Month visit window).
Time Frame	24 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.

Intent-to-treat population included all randomized participants.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Number of Participants Analyzed [units: participants]	**282**	**168**	**271**
Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months [units: Percentage of participants]	**15.2**	**16.1**	**15.1**

No statistical analysis provided for Percentage of Participants With Graft Loss/Re-transplant, Death or Loss to Follow-up at 24 Months

9. Secondary: Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months [Time Frame: 24 Months]

Measure Type	Secondary
Measure Title	Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months
Measure Description	GFR was calculated using the Modification of Diet and Renal Disease (MDRD) formula: GFR [mL/min/1.73m^2] = 186.3*(C^-1.154)*(A^-0.203)*G*R C is the serum concentration of creatinine [mg/dL] A is age [years] G=0.742 when gender is female, otherwise G=1 R=1.21 when race is black, otherwise R=1
Time Frame	24 Months
Safety Issue	Yes

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants from the intent-to-treat population (all randomized participants) with data available for analysis.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.

Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Number of Participants Analyzed [units: participants]	**227**	**132**	**127**
Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months [units: mL/min/1.73^2] Mean (Standard Deviation)	**59.50 (22.438)**	**61.84 (25.247)**	**64.52 (23.764)**

No statistical analysis provided for Renal Function Calculated by Glomerular Filtration Rate (GFR) at 24 Months

10. Secondary: Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24 [Time Frame: 24 Months]

Measure Type	Secondary
Measure Title	Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24
Measure Description	Identification of acute rejections was based on the local pathologist's evaluation of endomyocardial biopsy slides. Hemodynamic compromise was present if 1 or more of the following were met: Ejection fraction ≤ 30% or 25% lower than Baseline or Fractional shortening ≤ 20% or 25% lower than Baseline, and/ or use of inotropic treatment.
Time Frame	24 Months
Safety Issue	No

Population Description

Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Intent-to-treat population included all randomized participants.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Measured Values

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Number of Participants Analyzed [units: participants]	**282**	**168**	**271**

Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24 [units: Percentage of participants]			
AR associated with HDC	**4.3**	**3.6**	**5.2**
BPAR of ISHLT grade ≥ 3A	**24.1**	**28.6**	**27.3**
Death	**10.6**	**11.9**	**9.2**
Graft loss/re-transplant	**2.5**	**3.0**	**3.7**

No statistical analysis provided for Percentage of Participants With Biopsy-proven Acute Rejection (BPAR of ISHLT Grade ≥ 3A), Acute Rejection (AR) Associated With Hemodynamic Compromise (HDC), Graft Loss/Re-transplant and Death at Month 24

Serious Adverse Events

Hide Serious Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Serious Adverse Events

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Total, serious adverse events			
# participants affected / at risk	**209/279 (74.91%)**	**119/167 (71.26%)**	**168/268 (62.69%)**
Blood and lymphatic system disorders			
Anaemia † 1			
# participants affected / at risk	**5/279 (1.79%)**	**5/167 (2.99%)**	**4/268 (1.49%)**
Bone marrow failure † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Coagulopathy † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Febrile neutropenia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Haemolytic anaemia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Leukocytosis † 1			

# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Leukopenia † 1			
# participants affected / at risk	1/279 (0.36%)	4/167 (2.40%)	2/268 (0.75%)
Neutropenia † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)
Pancytopenia † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	1/268 (0.37%)
Thrombocytopenia † 1			
# participants affected / at risk	1/279 (0.36%)	2/167 (1.20%)	1/268 (0.37%)
Thrombotic microangiopathy † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Thrombotic thrombocytopenic purpura † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Cardiac disorders			
Acute myocardial infarction † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Angina pectoris † 1			
# participants affected / at risk	4/279 (1.43%)	2/167 (1.20%)	0/268 (0.00%)
Aortic valve incompetence † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Arrhythmia † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	2/268 (0.75%)
Atrial fibrillation † 1			
# participants affected / at risk	7/279 (2.51%)	3/167 (1.80%)	10/268 (3.73%)
Atrial flutter † 1			
# participants affected / at risk	4/279 (1.43%)	1/167 (0.60%)	5/268 (1.87%)
Atrial tachycardia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	2/268 (0.75%)
Atrial thrombosis † 1			
# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	2/268 (0.75%)
Atrioventricular block † 1			
# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	1/268 (0.37%)
Atrioventricular block complete † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	1/268 (0.37%)
Atrioventricular block second degree † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Bradycardia † 1			
# participants affected / at risk	2/279 (0.72%)	1/167 (0.60%)	0/268 (0.00%)
Cardiac arrest † 1			
# participants affected / at risk	3/279 (1.08%)	5/167 (2.99%)	3/268 (1.12%)
Cardiac failure † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	2/268 (0.75%)
Cardiac failure acute † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)

Cardiac failure congestive † 1			
# participants affected / at risk	**4/279 (1.43%)**	**1/167 (0.60%)**	**4/268 (1.49%)**
Cardiac perforation † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Cardiac tamponade † 1			
# participants affected / at risk	**5/279 (1.79%)**	**3/167 (1.80%)**	**4/268 (1.49%)**
Cardio-respiratory arrest † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Cardiogenic shock † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**6/268 (2.24%)**
Cardiomegaly † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Coronary artery disease † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Coronary artery dissection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Coronary artery occlusion † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Coronary artery stenosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Dilatation atrial † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Ischaemic cardiomyopathy † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Left ventricular dysfunction † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Nodal arrhythmia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Nodal rhythm † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Palpitations † 1			
# participants affected / at risk	**5/279 (1.79%)**	**0/167 (0.00%)**	**4/268 (1.49%)**
Pericardial cyst † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pericardial effusion † 1			
# participants affected / at risk	**38/279 (13.62%)**	**18/167 (10.78%)**	**12/268 (4.48%)**
Pericardial haemorrhage † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pericarditis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Pericarditis constrictive † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pulseless electrical activity † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**1/268 (0.37%)**

Right ventricular dysfunction † 1			
# participants affected / at risk	**2/279 (0.72%)**	**3/167 (1.80%)**	**0/268 (0.00%)**
Right ventricular failure † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Sick sinus syndrome † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Sinus arrest † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Supraventricular tachycardia † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Tachycardia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**3/268 (1.12%)**
Tricuspid valve incompetence † 1			
# participants affected / at risk	**3/279 (1.08%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Ventricular arrhythmia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Ventricular asystole † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Ventricular dysfunction † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Ventricular extrasystoles † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Ventricular fibrillation † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Ventricular tachycardia † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Ear and labyrinth disorders			
Vertigo † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Endocrine disorders			
Adrenal insufficiency † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Hyperthyroidism † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Eye disorders			
Blindness † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Retinal artery thrombosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Vision blurred † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Visual impairment † 1			
# participants affected / at risk	**0/279 (0.00%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Vitreous haemorrhage † 1			

# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Gastrointestinal disorders			
Abdominal discomfort † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Abdominal distension † 1			
# participants affected / at risk	2/279 (0.72%)	0/167 (0.00%)	1/268 (0.37%)
Abdominal hernia † 1			
# participants affected / at risk	4/279 (1.43%)	3/167 (1.80%)	1/268 (0.37%)
Abdominal pain † 1			
# participants affected / at risk	2/279 (0.72%)	2/167 (1.20%)	3/268 (1.12%)
Abdominal pain upper † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)
Ascites † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Colitis † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Colitis ulcerative † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Diarrhoea † 1			
# participants affected / at risk	5/279 (1.79%)	2/167 (1.20%)	5/268 (1.87%)
Duodenal ulcer haemorrhage † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Dyspepsia † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Enteritis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Epigastric discomfort † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Gastrointestinal haemorrhage † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	3/268 (1.12%)
Gastrooesophageal reflux disease † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Gingival hyperplasia † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Hernial eventration † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Ileitis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Ileus † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Ileus paralytic † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Inguinal hernia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)

Intestinal ischaemia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Large intestinal ulcer † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Large intestine perforation † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Megacolon † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Melaena † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Nausea † 1			
# participants affected / at risk	**3/279 (1.08%)**	**4/167 (2.40%)**	**7/268 (2.61%)**
Odynophagia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Oesophagitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Oral disorder † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pancreatitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pancreatitis acute † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Paraesthesia oral † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Reflux oesophagitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Stomatitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Stomatitis necrotising † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Umbilical hernia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Upper gastrointestinal haemorrhage † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Vomiting † 1			
# participants affected / at risk	**4/279 (1.43%)**	**3/167 (1.80%)**	**5/268 (1.87%)**
General disorders			
Asthenia † 1			
# participants affected / at risk	**3/279 (1.08%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Cardiac death † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Catheter site haematoma † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Chest pain † 1			

# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Chills † 1			
# participants affected / at risk	3/279 (1.08%)	4/167 (2.40%)	2/268 (0.75%)
Concomitant disease progression † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Crepitations † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Device breakage † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Device malfunction † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Fatigue † 1			
# participants affected / at risk	2/279 (0.72%)	2/167 (1.20%)	6/268 (2.24%)
Feeling hot † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Generalised oedema † 1			
# participants affected / at risk	2/279 (0.72%)	1/167 (0.60%)	0/268 (0.00%)
Hyperpyrexia † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Hyperthermia † 1			
# participants affected / at risk	2/279 (0.72%)	1/167 (0.60%)	0/268 (0.00%)
Hypothermia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Impaired healing † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	2/268 (0.75%)
Malaise † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Multi-organ failure † 1			
# participants affected / at risk	6/279 (2.15%)	3/167 (1.80%)	5/268 (1.87%)
Non-cardiac chest pain † 1			
# participants affected / at risk	8/279 (2.87%)	2/167 (1.20%)	3/268 (1.12%)
Oedema † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Oedema peripheral † 1			
# participants affected / at risk	6/279 (2.15%)	5/167 (2.99%)	4/268 (1.49%)
Pyrexia † 1			
# participants affected / at risk	12/279 (4.30%)	14/167 (8.38%)	10/268 (3.73%)
Sudden cardiac death † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Sudden death † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Systemic inflammatory response syndrome † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Hepatobiliary disorders			

Bile duct stone † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Cholangitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Cholecystitis † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Cholecystitis acute † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Cholecystitis chronic † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Cholelithiasis † 1			
# participants affected / at risk	**3/279 (1.08%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Cholestasis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Hepatic failure † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Hepatitis acute † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Hepatorenal syndrome † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Ischaemic hepatitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Immune system disorders			
Allergy to animal † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Anaphylactic shock † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Drug hypersensitivity † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Heart transplant rejection † 1			
# participants affected / at risk	**20/279 (7.17%)**	**13/167 (7.78%)**	**26/268 (9.70%)**
Hypersensitivity † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Transplant rejection † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Infections and infestations			
Abscess intestinal † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Abscess limb † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Abscess neck † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Acute pulmonary histoplasmosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**

Acute sinusitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Appendicitis † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Aspergillosis † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Bacteraemia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Bacterial diarrhoea † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Brain abscess † 1			
# participants affected / at risk	**0/279 (0.00%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Bronchiolitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Bronchitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**2/268 (0.75%)**
Bronchitis bacterial † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Bronchopulmonary aspergillosis † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Candida pneumonia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Cellulitis † 1			
# participants affected / at risk	**2/279 (0.72%)**	**2/167 (1.20%)**	**2/268 (0.75%)**
Cerebral aspergillosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Chlamydial infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Clostridial infection † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Clostridium difficile colitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Cytomegalovirus colitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Cytomegalovirus gastritis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Cytomegalovirus infection † 1			
# participants affected / at risk	**3/279 (1.08%)**	**5/167 (2.99%)**	**10/268 (3.73%)**
Cytomegalovirus syndrome † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**3/268 (1.12%)**
Cytomegalovirus viraemia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**8/268 (2.99%)**
Device related infection † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**0/268 (0.00%)**

Device related sepsis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Diarrhoea infectious † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Endocarditis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Enterobacter bacteraemia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Enterobacter infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Enterobacter pneumonia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Enterococcal infection † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Escherichia infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Escherichia sepsis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Fungal abscess central nervous system † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Fungal infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Fungal peritonitis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Fungal sepsis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Gastroenteritis † 1			
# participants affected / at risk	**4/279 (1.43%)**	**1/167 (0.60%)**	**4/268 (1.49%)**
Gastroenteritis viral † 1			
# participants affected / at risk	**3/279 (1.08%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Gastrointestinal infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
H1N1 influenza † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Herpes simplex † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Herpes virus infection † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Herpes zoster † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**3/268 (1.12%)**
Herpes zoster disseminated † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Incision site infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**

Infected lymphocele † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Infection † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Influenza † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Intraspinal abscess † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Listeriosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Lobar pneumonia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**3/268 (1.12%)**
Lower respiratory tract infection † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Lung abscess † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Lung infection † 1			
# participants affected / at risk	**5/279 (1.79%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Lung infection pseudomonal † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Mediastinitis † 1			
# participants affected / at risk	**4/279 (1.43%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Meningitis cryptococcal † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Mycobacterium avium complex infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Mycobacterium chelonei infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Myocarditis mycotic † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Necrotising fasciitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Oral herpes † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Osteomyelitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**3/167 (1.80%)**	**2/268 (0.75%)**
Pericarditis fungal † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pneumococcal sepsis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pneumocystis jiroveci pneumonia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Pneumonia † 1			
# participants affected / at risk	**15/279 (5.38%)**	**11/167 (6.59%)**	**8/268 (2.99%)**

Pneumonia bacterial † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pneumonia cryptococcal † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Pneumonia cytomegaloviral † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**3/268 (1.12%)**
Pneumonia escherichia † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pneumonia haemophilus † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pneumonia klebsiella † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Pneumonia legionella † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pneumonia pneumococcal † 1			
# participants affected / at risk	**3/279 (1.08%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Pneumonia primary atypical † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Pneumonia respiratory syncytial viral † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Post procedural pneumonia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Postoperative wound infection † 1			
# participants affected / at risk	**5/279 (1.79%)**	**5/167 (2.99%)**	**2/268 (0.75%)**
Pseudomembranous colitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Pseudomonas bronchitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Purulent pericarditis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pyelonephritis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pyothorax † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Respiratory tract infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Respiratory tract infection viral † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Rhinovirus infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Salmonella sepsis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Sepsis † 1			
# participants affected / at risk	**7/279 (2.51%)**	**6/167 (3.59%)**	**2/268 (0.75%)**

Sepsis syndrome † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Septic embolus † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Septic shock † 1			
# participants affected / at risk	**4/279 (1.43%)**	**3/167 (1.80%)**	**2/268 (0.75%)**
Sinusitis † 1			
# participants affected / at risk	**3/279 (1.08%)**	**2/167 (1.20%)**	**2/268 (0.75%)**
Skin infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Spinal cord infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Staphylococcal bacteraemia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Staphylococcal mediastinitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Staphylococcal sepsis † 1			
# participants affected / at risk	**3/279 (1.08%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Stenotrophomonas infection † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Tonsillitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Tooth infection † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Tracheobronchitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Tuberculosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Upper respiratory tract infection † 1			
# participants affected / at risk	**3/279 (1.08%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Urinary tract infection † 1			
# participants affected / at risk	**5/279 (1.79%)**	**0/167 (0.00%)**	**5/268 (1.87%)**
Urosepsis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Varicella † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Viral infection † 1			
# participants affected / at risk	**3/279 (1.08%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Viral upper respiratory tract infection † 1			
# participants affected / at risk	**5/279 (1.79%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Wound infection † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Wound infection staphylococcal † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**2/268 (0.75%)**

Injury, poisoning and procedural complications			
Alcohol poisoning † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Arterial injury † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Cervical vertebral fracture † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Complications of transplanted heart † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Contrast media reaction † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Contusion † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Dislocation of sternum † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Extradural haematoma † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Fall † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Femoral neck fracture † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Femur fracture † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Foot fracture † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Gastrointestinal anastomotic leak † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Head injury † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Incision site pain † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Incisional hernia † 1			
# participants affected / at risk	**3/279 (1.08%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Jaw fracture † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Ligament rupture † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Lumbar vertebral fracture † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Pelvic fracture † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Post procedural complication † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Post procedural diarrhoea † 1			

# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Post procedural discharge † 1			
# participants affected / at risk	1/279 (0.36%)	2/167 (1.20%)	1/268 (0.37%)
Post procedural haemorrhage † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	1/268 (0.37%)
Post procedural swelling † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Post-traumatic pain † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Postoperative thoracic procedure complication † 1			
# participants affected / at risk	2/279 (0.72%)	0/167 (0.00%)	4/268 (1.49%)
Postoperative wound complication † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Rib fracture † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Road traffic accident † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Seroma † 1			
# participants affected / at risk	4/279 (1.43%)	2/167 (1.20%)	0/268 (0.00%)
Spinal fracture † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)
Toxicity to various agents † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	1/268 (0.37%)
Vascular pseudoaneurysm † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Wound dehiscence † 1			
# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	1/268 (0.37%)
Investigations			
Atrial pressure increased † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Blood creatine phosphokinase increased † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Blood creatinine increased † 1			
# participants affected / at risk	4/279 (1.43%)	2/167 (1.20%)	1/268 (0.37%)
Blood potassium increased † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Blood pressure increased † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Catheterisation cardiac † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Cells in urine † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Central venous pressure increased † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)

Culture wound positive † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Cytomegalovirus test positive † 1			
# participants affected / at risk	**0/279 (0.00%)**	**2/167 (1.20%)**	**2/268 (0.75%)**
Ejection fraction decreased † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Haemoglobin decreased † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Immunosuppressant drug level † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Immunosuppressant drug level decreased † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Immunosuppressant drug level increased † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Left ventricular end-diastolic pressure increased † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Liver function test abnormal † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Red blood cell count decreased † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Sputum culture positive † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Troponin increased † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Weight increased † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
White blood cell count decreased † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Metabolism and nutrition disorders			
Dehydration † 1			
# participants affected / at risk	**4/279 (1.43%)**	**2/167 (1.20%)**	**2/268 (0.75%)**
Diabetes mellitus † 1			
# participants affected / at risk	**3/279 (1.08%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Diabetic foot † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Diabetic ketoacidosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Failure to thrive † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Fluid overload † 1			
# participants affected / at risk	**6/279 (2.15%)**	**6/167 (3.59%)**	**6/268 (2.24%)**
Fluid retention † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Gout † 1			

# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)
Hyperglycaemia † 1			
# participants affected / at risk	3/279 (1.08%)	1/167 (0.60%)	1/268 (0.37%)
Hyperkalaemia † 1			
# participants affected / at risk	1/279 (0.36%)	2/167 (1.20%)	4/268 (1.49%)
Hypervolaemia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Hypoalbuminaemia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Hypoglycaemia † 1			
# participants affected / at risk	3/279 (1.08%)	2/167 (1.20%)	2/268 (0.75%)
Hypokalaemia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Hyponatraemia † 1			
# participants affected / at risk	3/279 (1.08%)	0/167 (0.00%)	0/268 (0.00%)
Metabolic acidosis † 1			
# participants affected / at risk	2/279 (0.72%)	2/167 (1.20%)	0/268 (0.00%)
Metabolic disorder † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Musculoskeletal and connective tissue disorders			
Arthralgia † 1			
# participants affected / at risk	2/279 (0.72%)	1/167 (0.60%)	0/268 (0.00%)
Back pain † 1			
# participants affected / at risk	1/279 (0.36%)	3/167 (1.80%)	4/268 (1.49%)
Bone lesion † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Compartment syndrome † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Fistula † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Haemarthrosis † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Intervertebral disc compression † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Intervertebral disc protrusion † 1			
# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	2/268 (0.75%)
Mobility decreased † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Musculoskeletal chest pain † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Musculoskeletal pain † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	1/268 (0.37%)
Myalgia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	1/268 (0.37%)

Myopathy † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Neck pain † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Osteochondrosis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Osteonecrosis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**0/268 (0.00%)**
Osteoporosis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pain in extremity † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Rhabdomyolysis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**1/268 (0.37%)**
Spinal column stenosis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Spondylitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Basal cell carcinoma † 1			
# participants affected / at risk	**4/279 (1.43%)**	**3/167 (1.80%)**	**2/268 (0.75%)**
Benign neoplasm of skin † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Bladder transitional cell carcinoma † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Colon cancer † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Diffuse large B-cell lymphoma † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Epstein-Barr virus associated lymphoproliferative disorder † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Haemangioma † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Lipoma † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Lung neoplasm † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Lung neoplasm malignant † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Malignant melanoma † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Ovarian cancer † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Prostate cancer † 1			

# participants affected / at risk	2/279 (0.72%)	1/167 (0.60%)	0/268 (0.00%)
Small cell lung cancer stage unspecified † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Squamous cell carcinoma † 1			
# participants affected / at risk	1/279 (0.36%)	2/167 (1.20%)	1/268 (0.37%)
Squamous cell carcinoma of skin † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Nervous system disorders			
Amnesia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Aphasia † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Ataxia † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Basal ganglia haemorrhage † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Brain injury † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Brain stem infarction † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Cerebral artery occlusion † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Cerebral haemorrhage † 1			
# participants affected / at risk	2/279 (0.72%)	2/167 (1.20%)	1/268 (0.37%)
Cerebral infarction † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Cerebrovascular accident † 1			
# participants affected / at risk	2/279 (0.72%)	2/167 (1.20%)	1/268 (0.37%)
Cerebrovascular insufficiency † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Cognitive disorder † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Coma † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Convulsion † 1			
# participants affected / at risk	4/279 (1.43%)	1/167 (0.60%)	2/268 (0.75%)
Depressed level of consciousness † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Dizziness † 1			
# participants affected / at risk	2/279 (0.72%)	3/167 (1.80%)	2/268 (0.75%)
Encephalopathy † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Grand mal convulsion † 1			
# participants affected / at risk	2/279 (0.72%)	1/167 (0.60%)	0/268 (0.00%)

Haemorrhage intracranial † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Headache † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Hemiparesis † 1			
# participants affected / at risk	**2/279 (0.72%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Hypoaesthesia † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Hypoxic-ischaemic encephalopathy † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Loss of consciousness † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Migraine † 1			
# participants affected / at risk	**1/279 (0.36%)**	**2/167 (1.20%)**	**1/268 (0.37%)**
Neurological symptom † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Neuropathy peripheral † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Paraesthesia † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**2/268 (0.75%)**
Polyneuropathy † 1			
# participants affected / at risk	**2/279 (0.72%)**	**1/167 (0.60%)**	**4/268 (1.49%)**
Sciatica † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Subarachnoid haemorrhage † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Syncope † 1			
# participants affected / at risk	**5/279 (1.79%)**	**1/167 (0.60%)**	**6/268 (2.24%)**
Thalamic infarction † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Transient ischaemic attack † 1			
# participants affected / at risk	**1/279 (0.36%)**	**3/167 (1.80%)**	**1/268 (0.37%)**
Tremor † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Psychiatric disorders			
Abnormal behaviour † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Alcohol abuse † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Anxiety † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**3/268 (1.12%)**
Confusional state † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**2/268 (0.75%)**
Delirium † 1			

# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	1/268 (0.37%)
Depression † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	2/268 (0.75%)
Drug abuse † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Hallucination † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Mental disorder † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Mental status changes † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	3/268 (1.12%)
Suicide attempt † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Renal and urinary disorders			
Azotaemia † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Calculus ureteric † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Haematuria † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Nephropathy toxic † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Nephrosclerosis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Polyuria † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Proteinuria † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Renal failure † 1			
# participants affected / at risk	10/279 (3.58%)	0/167 (0.00%)	3/268 (1.12%)
Renal failure acute † 1			
# participants affected / at risk	12/279 (4.30%)	13/167 (7.78%)	13/268 (4.85%)
Renal failure chronic † 1			
# participants affected / at risk	1/279 (0.36%)	2/167 (1.20%)	0/268 (0.00%)
Renal impairment † 1			
# participants affected / at risk	3/279 (1.08%)	0/167 (0.00%)	1/268 (0.37%)
Renal tubular necrosis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Reproductive system and breast disorders			
Colpocele † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Epididymitis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Oedema genital † 1			

# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Respiratory, thoracic and mediastinal disorders			
Acute respiratory distress syndrome † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Acute respiratory failure † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Apnoea † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Bronchial haemorrhage † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Chronic obstructive pulmonary disease † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)
Chylothorax † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Cough † 1			
# participants affected / at risk	2/279 (0.72%)	3/167 (1.80%)	0/268 (0.00%)
Diaphragmatic paralysis † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Dyspnoea † 1			
# participants affected / at risk	14/279 (5.02%)	8/167 (4.79%)	8/268 (2.99%)
Dyspnoea exertional † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	2/268 (0.75%)
Epistaxis † 1			
# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	0/268 (0.00%)
Haemothorax † 1			
# participants affected / at risk	3/279 (1.08%)	0/167 (0.00%)	0/268 (0.00%)
Hiccups † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Hypoxia † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Interstitial lung disease † 1			
# participants affected / at risk	0/279 (0.00%)	2/167 (1.20%)	1/268 (0.37%)
Lung infiltration † 1			
# participants affected / at risk	2/279 (0.72%)	0/167 (0.00%)	0/268 (0.00%)
Mediastinal haematoma † 1			
# participants affected / at risk	2/279 (0.72%)	0/167 (0.00%)	0/268 (0.00%)
Mediastinal mass † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Nasal congestion † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Nasal polyps † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Oropharyngeal pain † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)

Orthopnoea † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pleural effusion † 1			
# participants affected / at risk	**13/279 (4.66%)**	**4/167 (2.40%)**	**6/268 (2.24%)**
Pleural haemorrhage † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Pleuritic pain † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pneumonitis † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pneumothorax † 1			
# participants affected / at risk	**5/279 (1.79%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Productive cough † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pulmonary embolism † 1			
# participants affected / at risk	**5/279 (1.79%)**	**4/167 (2.40%)**	**2/268 (0.75%)**
Pulmonary hypertension † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Pulmonary infarction † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pulmonary oedema † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Pulmonary toxicity † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Respiratory arrest † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Respiratory distress † 1			
# participants affected / at risk	**1/279 (0.36%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Respiratory failure † 1			
# participants affected / at risk	**4/279 (1.43%)**	**2/167 (1.20%)**	**2/268 (0.75%)**
Rhinorrhoea † 1			
# participants affected / at risk	**0/279 (0.00%)**	**1/167 (0.60%)**	**0/268 (0.00%)**
Sputum discoloured † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Tracheal stenosis † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Skin and subcutaneous tissue disorders			
Blood blister † 1			
# participants affected / at risk	**1/279 (0.36%)**	**0/167 (0.00%)**	**0/268 (0.00%)**
Diabetic ulcer † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Excessive granulation tissue † 1			
# participants affected / at risk	**0/279 (0.00%)**	**0/167 (0.00%)**	**1/268 (0.37%)**
Hyperhidrosis † 1			

# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Night sweats † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Rash macular † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Skin lesion † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Subcutaneous emphysema † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Surgical and medical procedures			
Incisional drainage † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Vascular disorders			
Angiodysplasia † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Arteriovenous fistula † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Deep vein thrombosis † 1			
# participants affected / at risk	3/279 (1.08%)	2/167 (1.20%)	3/268 (1.12%)
Femoral artery aneurysm † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Flushing † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	1/268 (0.37%)
Haematoma † 1			
# participants affected / at risk	2/279 (0.72%)	0/167 (0.00%)	1/268 (0.37%)
Haemodynamic instability † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Hypertension † 1			
# participants affected / at risk	4/279 (1.43%)	2/167 (1.20%)	0/268 (0.00%)
Hypertensive crisis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Hypotension † 1			
# participants affected / at risk	3/279 (1.08%)	5/167 (2.99%)	4/268 (1.49%)
Intermittent claudication † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Intra-abdominal haemorrhage † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Jugular vein thrombosis † 1			
# participants affected / at risk	1/279 (0.36%)	1/167 (0.60%)	0/268 (0.00%)
Lymphocele † 1			
# participants affected / at risk	5/279 (1.79%)	1/167 (0.60%)	1/268 (0.37%)
Lymphoedema † 1			
# participants affected / at risk	0/279 (0.00%)	1/167 (0.60%)	0/268 (0.00%)
Lymphorrhoea † 1			

# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Malignant hypertension † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Peripheral ischaemia † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	2/268 (0.75%)
Phlebitis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Subclavian vein thrombosis † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	0/268 (0.00%)
Thrombosis † 1			
# participants affected / at risk	0/279 (0.00%)	0/167 (0.00%)	1/268 (0.37%)
Venous thrombosis limb † 1			
# participants affected / at risk	1/279 (0.36%)	0/167 (0.00%)	2/268 (0.75%)

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0

Other Adverse Events

Hide Other Adverse Events

Time Frame	No text entered.
Additional Description	No text entered.

Frequency Threshold

Threshold above which other adverse events are reported	5%

Reporting Groups

	Description
Everolimus 1.5 mg	Within 72 hours after transplantation participants received 0.75 mg everolimus tablets twice a day 12 hours apart for a total 1.5 mg daily dose in combination with reduced cyclosporine and standard corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 3-8 ng/mL.
Everolimus 3.0 mg	Within 72 hours after transplantation participants received 1.5 mg everolimus tablets twice a day 12 hours apart for a total 3.0 mg daily dose in combination with reduced cyclosporine and standard dose corticosteroids for 24 months. The everolimus dose could be adjusted to maintain a target everolimus trough level of 6-12 ng/mL.
Mycophenolate Mofetil	Within 72 hours after transplantation participants received 3 tablets 500 mg mycophenolate mofetil twice a day 12 hours apart for a total daily dose of 3000 mg in combination with a standard cyclosporine dose and standard dose corticosteroids for 24 months.

Other Adverse Events

	Everolimus 1.5 mg	Everolimus 3.0 mg	Mycophenolate Mofetil
Total, other (not including serious) adverse events			
# participants affected / at risk	275/279 (98.57%)	165/167 (98.80%)	262/268 (97.76%)
Blood and lymphatic system disorders			
Anaemia † 1			
# participants affected / at risk	105/279 (37.63%)	60/167 (35.93%)	74/268 (27.61%)
Leukocytosis † 1			
# participants affected / at risk	37/279 (13.26%)	27/167 (16.17%)	27/268 (10.07%)

Leukopenia † 1			
# participants affected / at risk	**36/279 (12.90%)**	**29/167 (17.37%)**	**67/268 (25.00%)**
Neutropenia † 1			
# participants affected / at risk	**8/279 (2.87%)**	**4/167 (2.40%)**	**15/268 (5.60%)**
Thrombocytopenia † 1			
# participants affected / at risk	**26/279 (9.32%)**	**25/167 (14.97%)**	**25/268 (9.33%)**
Cardiac disorders			
Atrial fibrillation † 1			
# participants affected / at risk	**20/279 (7.17%)**	**13/167 (7.78%)**	**22/268 (8.21%)**
Left ventricular hypertrophy † 1			
# participants affected / at risk	**16/279 (5.73%)**	**5/167 (2.99%)**	**12/268 (4.48%)**
Mitral valve incompetence † 1			
# participants affected / at risk	**15/279 (5.38%)**	**7/167 (4.19%)**	**18/268 (6.72%)**
Palpitations † 1			
# participants affected / at risk	**12/279 (4.30%)**	**14/167 (8.38%)**	**14/268 (5.22%)**
Pericardial effusion † 1			
# participants affected / at risk	**93/279 (33.33%)**	**51/167 (30.54%)**	**69/268 (25.75%)**
Sinus tachycardia † 1			
# participants affected / at risk	**13/279 (4.66%)**	**9/167 (5.39%)**	**7/268 (2.61%)**
Tachycardia † 1			
# participants affected / at risk	**20/279 (7.17%)**	**14/167 (8.38%)**	**23/268 (8.58%)**
Tricuspid valve incompetence † 1			
# participants affected / at risk	**28/279 (10.04%)**	**17/167 (10.18%)**	**24/268 (8.96%)**
Gastrointestinal disorders			
Abdominal distension † 1			
# participants affected / at risk	**11/279 (3.94%)**	**8/167 (4.79%)**	**17/268 (6.34%)**
Abdominal pain † 1			
# participants affected / at risk	**29/279 (10.39%)**	**17/167 (10.18%)**	**26/268 (9.70%)**
Abdominal pain upper † 1			
# participants affected / at risk	**17/279 (6.09%)**	**9/167 (5.39%)**	**17/268 (6.34%)**
Constipation † 1			
# participants affected / at risk	**70/279 (25.09%)**	**42/167 (25.15%)**	**63/268 (23.51%)**
Diarrhoea † 1			
# participants affected / at risk	**62/279 (22.22%)**	**43/167 (25.75%)**	**67/268 (25.00%)**
Dyspepsia † 1			
# participants affected / at risk	**17/279 (6.09%)**	**9/167 (5.39%)**	**16/268 (5.97%)**
Nausea † 1			
# participants affected / at risk	**64/279 (22.94%)**	**52/167 (31.14%)**	**72/268 (26.87%)**
Vomiting † 1			
# participants affected / at risk	**33/279 (11.83%)**	**21/167 (12.57%)**	**45/268 (16.79%)**
General disorders			
Asthenia † 1			
# participants affected / at risk	**16/279 (5.73%)**	**12/167 (7.19%)**	**21/268 (7.84%)**
Chills † 1			

# participants affected / at risk	12/279 (4.30%)	12/167 (7.19%)	13/268 (4.85%)
Fatigue † 1			
# participants affected / at risk	39/279 (13.98%)	22/167 (13.17%)	50/268 (18.66%)
Non-cardiac chest pain † 1			
# participants affected / at risk	38/279 (13.62%)	10/167 (5.99%)	26/268 (9.70%)
Oedema peripheral † 1			
# participants affected / at risk	133/279 (47.67%)	69/167 (41.32%)	119/268 (44.40%)
Pyrexia † 1			
# participants affected / at risk	47/279 (16.85%)	22/167 (13.17%)	38/268 (14.18%)
Immune system disorders			
Heart transplant rejection † 1			
# participants affected / at risk	6/279 (2.15%)	2/167 (1.20%)	15/268 (5.60%)
Infections and infestations			
Bronchitis † 1			
# participants affected / at risk	7/279 (2.51%)	7/167 (4.19%)	15/268 (5.60%)
Cytomegalovirus infection † 1			
# participants affected / at risk	14/279 (5.02%)	7/167 (4.19%)	25/268 (9.33%)
Herpes zoster † 1			
# participants affected / at risk	8/279 (2.87%)	4/167 (2.40%)	23/268 (8.58%)
Nasopharyngitis † 1			
# participants affected / at risk	35/279 (12.54%)	12/167 (7.19%)	32/268 (11.94%)
Oral candidiasis † 1			
# participants affected / at risk	10/279 (3.58%)	3/167 (1.80%)	14/268 (5.22%)
Oral herpes † 1			
# participants affected / at risk	7/279 (2.51%)	9/167 (5.39%)	15/268 (5.60%)
Upper respiratory tract infection † 1			
# participants affected / at risk	34/279 (12.19%)	16/167 (9.58%)	32/268 (11.94%)
Urinary tract infection † 1			
# participants affected / at risk	18/279 (6.45%)	19/167 (11.38%)	20/268 (7.46%)
Injury, poisoning and procedural complications			
Incision site pain † 1			
# participants affected / at risk	20/279 (7.17%)	19/167 (11.38%)	20/268 (7.46%)
Post procedural discharge † 1			
# participants affected / at risk	14/279 (5.02%)	6/167 (3.59%)	7/268 (2.61%)
Procedural pain † 1			
# participants affected / at risk	35/279 (12.54%)	24/167 (14.37%)	32/268 (11.94%)
Investigations			
Blood creatinine increased † 1			
# participants affected / at risk	25/279 (8.96%)	17/167 (10.18%)	18/268 (6.72%)
Blood triglycerides increased † 1			
# participants affected / at risk	13/279 (4.66%)	9/167 (5.39%)	7/268 (2.61%)
Cytomegalovirus test positive † 1			
# participants affected / at risk	4/279 (1.43%)	9/167 (5.39%)	18/268 (6.72%)
Haemoglobin decreased † 1			

# participants affected / at risk	19/279 (6.81%)	6/167 (3.59%)	22/268 (8.21%)
Weight increased † 1			
# participants affected / at risk	14/279 (5.02%)	5/167 (2.99%)	15/268 (5.60%)
White blood cell count decreased † 1			
# participants affected / at risk	11/279 (3.94%)	12/167 (7.19%)	35/268 (13.06%)
Metabolism and nutrition disorders			
Decreased appetite † 1			
# participants affected / at risk	10/279 (3.58%)	11/167 (6.59%)	8/268 (2.99%)
Diabetes mellitus † 1			
# participants affected / at risk	20/279 (7.17%)	8/167 (4.79%)	22/268 (8.21%)
Fluid overload † 1			
# participants affected / at risk	47/279 (16.85%)	30/167 (17.96%)	43/268 (16.04%)
Gout † 1			
# participants affected / at risk	15/279 (5.38%)	6/167 (3.59%)	7/268 (2.61%)
Hypercholesterolaemia † 1			
# participants affected / at risk	38/279 (13.62%)	22/167 (13.17%)	23/268 (8.58%)
Hyperglycaemia † 1			
# participants affected / at risk	32/279 (11.47%)	21/167 (12.57%)	31/268 (11.57%)
Hyperkalaemia † 1			
# participants affected / at risk	34/279 (12.19%)	17/167 (10.18%)	34/268 (12.69%)
Hyperlipidaemia † 1			
# participants affected / at risk	22/279 (7.89%)	9/167 (5.39%)	10/268 (3.73%)
Hypertriglyceridaemia † 1			
# participants affected / at risk	41/279 (14.70%)	23/167 (13.77%)	30/268 (11.19%)
Hypoglycaemia † 1			
# participants affected / at risk	15/279 (5.38%)	10/167 (5.99%)	18/268 (6.72%)
Hypokalaemia † 1			
# participants affected / at risk	39/279 (13.98%)	25/167 (14.97%)	32/268 (11.94%)
Hypomagnesaemia † 1			
# participants affected / at risk	21/279 (7.53%)	20/167 (11.98%)	37/268 (13.81%)
Musculoskeletal and connective tissue disorders			
Arthralgia † 1			
# participants affected / at risk	23/279 (8.24%)	13/167 (7.78%)	30/268 (11.19%)
Back pain † 1			
# participants affected / at risk	51/279 (18.28%)	17/167 (10.18%)	42/268 (15.67%)
Muscle spasms † 1			
# participants affected / at risk	41/279 (14.70%)	21/167 (12.57%)	36/268 (13.43%)
Muscular weakness † 1			
# participants affected / at risk	19/279 (6.81%)	6/167 (3.59%)	10/268 (3.73%)
Musculoskeletal chest pain † 1			
# participants affected / at risk	16/279 (5.73%)	4/167 (2.40%)	13/268 (4.85%)
Musculoskeletal pain † 1			
# participants affected / at risk	14/279 (5.02%)	9/167 (5.39%)	18/268 (6.72%)
Myalgia † 1			

# participants affected / at risk	24/279 (8.60%)	11/167 (6.59%)	18/268 (6.72%)
Pain in extremity † 1			
# participants affected / at risk	28/279 (10.04%)	9/167 (5.39%)	25/268 (9.33%)
Nervous system disorders			
Dizziness † 1			
# participants affected / at risk	37/279 (13.26%)	19/167 (11.38%)	27/268 (10.07%)
Headache † 1			
# participants affected / at risk	85/279 (30.47%)	39/167 (23.35%)	70/268 (26.12%)
Paraesthesia † 1			
# participants affected / at risk	23/279 (8.24%)	10/167 (5.99%)	17/268 (6.34%)
Tremor † 1			
# participants affected / at risk	58/279 (20.79%)	33/167 (19.76%)	60/268 (22.39%)
Psychiatric disorders			
Anxiety † 1			
# participants affected / at risk	41/279 (14.70%)	22/167 (13.17%)	35/268 (13.06%)
Depression † 1			
# participants affected / at risk	27/279 (9.68%)	14/167 (8.38%)	26/268 (9.70%)
Insomnia † 1			
# participants affected / at risk	77/279 (27.60%)	32/167 (19.16%)	60/268 (22.39%)
Renal and urinary disorders			
Renal failure † 1			
# participants affected / at risk	44/279 (15.77%)	25/167 (14.97%)	27/268 (10.07%)
Renal impairment † 1			
# participants affected / at risk	23/279 (8.24%)	8/167 (4.79%)	13/268 (4.85%)
Reproductive system and breast disorders			
Erectile dysfunction † 1			
# participants affected / at risk	16/279 (5.73%)	6/167 (3.59%)	9/268 (3.36%)
Respiratory, thoracic and mediastinal disorders			
Atelectasis † 1			
# participants affected / at risk	15/279 (5.38%)	7/167 (4.19%)	20/268 (7.46%)
Cough † 1			
# participants affected / at risk	67/279 (24.01%)	23/167 (13.77%)	51/268 (19.03%)
Dyspnoea † 1			
# participants affected / at risk	54/279 (19.35%)	25/167 (14.97%)	47/268 (17.54%)
Dyspnoea exertional † 1			
# participants affected / at risk	13/279 (4.66%)	9/167 (5.39%)	16/268 (5.97%)
Epistaxis † 1			
# participants affected / at risk	17/279 (6.09%)	11/167 (6.59%)	9/268 (3.36%)
Nasal congestion † 1			
# participants affected / at risk	14/279 (5.02%)	9/167 (5.39%)	9/268 (3.36%)
Oropharyngeal pain † 1			
# participants affected / at risk	21/279 (7.53%)	9/167 (5.39%)	16/268 (5.97%)
Pleural effusion † 1			
# participants affected / at risk	65/279 (23.30%)	37/167 (22.16%)	57/268 (21.27%)

Pneumothorax † 1			
# participants affected / at risk	**15/279 (5.38%)**	**4/167 (2.40%)**	**8/268 (2.99%)**
Productive cough † 1			
# participants affected / at risk	**15/279 (5.38%)**	**5/167 (2.99%)**	**10/268 (3.73%)**
Pulmonary hypertension † 1			
# participants affected / at risk	**11/279 (3.94%)**	**10/167 (5.99%)**	**18/268 (6.72%)**
Skin and subcutaneous tissue disorders			
Acne † 1			
# participants affected / at risk	**23/279 (8.24%)**	**18/167 (10.78%)**	**28/268 (10.45%)**
Hirsutism † 1			
# participants affected / at risk	**8/279 (2.87%)**	**9/167 (5.39%)**	**6/268 (2.24%)**
Rash † 1			
# participants affected / at risk	**15/279 (5.38%)**	**17/167 (10.18%)**	**17/268 (6.34%)**
Vascular disorders			
Hypertension † 1			
# participants affected / at risk	**132/279 (47.31%)**	**72/167 (43.11%)**	**125/268 (46.64%)**
Hypotension † 1			
# participants affected / at risk	**23/279 (8.24%)**	**13/167 (7.78%)**	**27/268 (10.07%)**
Jugular vein thrombosis † 1			
# participants affected / at risk	**14/279 (5.02%)**	**4/167 (2.40%)**	**5/268 (1.87%)**

† Events were collected by systematic assessment
1 Term from vocabulary, MedDRA 14.0

Limitations and Caveats

Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

More Information

Hide More Information

Certain Agreements:

Principal Investigators are **NOT** employed by the organization sponsoring the study.

There **IS** an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

The agreement is:

☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **less than or equal to 60 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.

☐ The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is **more than 60 days but less than or equal to 180 days**. The sponsor cannot require changes to the communication and cannot extend the embargo.

Other disclosure agreement that restricts the right of the PI to discuss or publish trial results after the trial is completed.

Restriction Description: The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not

prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial.

Results Point of Contact:

Name/Title: Study Director
Organization: Novartis Pharmaceuticals
phone: 862-778-8300

No publications provided

Responsible Party:	Novartis (Novartis Pharmaceuticals)
ClinicalTrials.gov Identifier:	NCT00300274 History of Changes
Other Study ID Numbers:	**CRAD001A2310**
Study First Received:	March 6, 2006
Results First Received:	July 6, 2012
Last Updated:	July 10, 2012
Health Authority:	United States: Food and Drug Administration